The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
The Role of Serotonin in Schizophrenia
Abstract
Studies examining serotonin (5-hydroxytryptamine; 5HT) in schizophrenia show variable and inconsistent findings, which might reflect the heterogeneity of the disease. When these studies are reviewed in the light of Crow's "two-syndrome" paradigm of schizophrenia, a new trend emerges. It appears that 5HT findings may be related to certain features of Type II schizophrenia such as negative symptoms, degenerative brain changes, and chronicity in the following manner: (1) 5HT2 antagonists, which have recently become available, have been shown to have an antipsychotic effect, particularly on the negative symptom cluster. (2) Decreased levels of 5-hydroxyindoleacetic acid in cerebrospinal fluid have been found to be correlated with cortical atrophy or ventricular enlargement in schizophrenic patients. (3) A subgroup of chronic schizophrenic patients has been shown to have elevated levels of platelet or whole blood 5HT. We propose, then, that 5HT dysfunction might be related to Type II, or negative syndrome, schizophrenia, and that the nature of this dysfunction might involve 5HT postsynaptic receptor hypersensitivity. We further suggest that the pharmacotherapy of schizophrenia should include a 5HT-blocking component, as well as a dopamine-blocking component, and we propose that future research should address the role of selective 5HT receptor hypersensitivity in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856
p-CHLOROPHENYLALANINE: A SPECIFIC DEPLETOR OF BRAIN SEROTONIN
Koe, B. K., & Weissman, A. (1966) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)27497-3 · Cited by 1,783
Positron Emission Tomography Reveals Elevated D 2 Dopamine Receptors in Drug-Naive Schizophrenics
Wong, D. F., Wagner, H. N., Tune, L. E., Dannals, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Broussolle, E. P., Ravert, H. T., Wilson, A. A., et al. (1986) · Science · doi:10.1126/science.2878495 · Cited by 932
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Precursor control of neurotransmitter synthesis.
Wurtman, R. J., Hefti, F., & Melamed, E. (1980) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06841-3 · Cited by 671
Charney, D. S. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780350094011 · Cited by 649
Two Distinct Central Serotonin Receptors with Different Physiological Functions
Peroutka, S. J., Lebovitz, R. M., & Snyder, S. H. (1981) · Science · doi:10.1126/science.7221567 · Cited by 637
Serotonergic component of neuroleptic receptors
LEYSEN, J. E., NIEMEGEERS, C. J. E., TOLLENAERE, J. P., & LADURON, P. M. (1978) · Nature · doi:10.1038/272168a0 · Cited by 623
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 602
Amphetamine Psychosis: A "Model" Schizophrenia Mediated by Catecholamines
SNYDER, S. H. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.1.61 · Cited by 587
The dopamine hypothesis of schizophrenia: focus on the dopamine receptor
(1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.2.197 · Cited by 556
(1973) · Elsevier eBooks · doi:10.1016/b978-0-120-78150-8.x5001-4 · Cited by 539
Treatment of Negative Symptoms
Carpenter, W. T., Heinrichs, D. W., & Alphs, L. D. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.440 · Cited by 499
Leysen, J. E., Gommeren, W., Van Gompel, P., Wynants, J., Janssen, P. F., & Laduron, P. M. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12558-3 · Cited by 452
Catecholamines in the Brain as Mediators of Amphetamine Psychosis
Snyder, S. H. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750260021004 · Cited by 432
Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.3.297 · Cited by 426
Blood platelets as a model for monoamine-containing neurones
Sneddon, J. M. (1973) · Progress in Neurobiology · doi:10.1016/0301-0082(73)90019-1 · Cited by 404
Receptors for neurotransmitters and peptide hormones.
Pepeu, G., Kuhar, M. J., & Enna, S. J. (1980) · PubMed · Cited by 376
Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Sharman, D. F., Macdougall, E., Stanton, J. B., & Binns, J. K. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92028-9 · Cited by 373
Wolfstein, &. (1905) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-190502000-00009 · Cited by 344
Sills, M. A., Wolfe, B. B., & Frazer, A. (1984) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21645-7 · Cited by 331
Central Dopamine Turnover in Schizophrenic Syndromes
Bowers, M. B. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760130034005 · Cited by 270
Serotonin in biological psychiatry.
Ho, B. T., Schoolar, J. C., & Usdin, E. (1982) · PubMed · Cited by 264
Demonstration of specific high affinity binding sites for [3H] imipramine in human brain
Rehavi, M., Paul, S. M., Skolnick, P., & K. Goodwin, F. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90213-1 · Cited by 256
MILLER, R. J., HORN, A. S., & IVERSEN, L. L. (1974) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13988-6 · Cited by 256
Neurotransmitter Receptors in Frontal Cortex of Schizophrenics
Bennett, J. P. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780090013001 · Cited by 248
PNEUMOGRAPHIC FINDINGS IN THE INFANTILE AUTISM SYNDROME: A CORRELATION WITH TEMPORAL LOBE DISEASE
HAUSER, S. L., DELONG, G. R., & ROSMAN, N. P. (1975) · Brain · doi:10.1093/brain/98.4.667 · Cited by 244
Serotonin Uptake in Blood Platelets of Psychiatric Patients
Meltzer, H. Y. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780370024002 · Cited by 233
Hyperserotonemia and amine metabolites in autistic and retarded children
Hanley, H. G. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770170031002 · Cited by 230
Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics
Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamadori, T., Mizoi, Y., & Tanaka, C. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90332-x · Cited by 222
CSF 5-hydroxyindoleacetic Acid levels in suicidal schizophrenic patients
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.4.566 · Cited by 219
Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings
Crow, T. J., Baker, H. F., Cross, A. J., Joseph, M. H., Lofthouse, R., Longden, A., Owen, F., Riley, G. J., Glover, V., & Killpack, W. S. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.3.249 · Cited by 213
Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients
Bowers, M. B., Heninger, G. R., & Gerbode, F. (1969) · International Journal of Neuropharmacology · doi:10.1016/0028-3908(69)90046-x · Cited by 211
CSF 5-HIAA AND SUICIDE IN NON-DEPRESSED SCHIZOPHRENICS
Van Praag, H. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90501-9 · Cited by 211
Self-citationCerebrospinal Fluid Amine Metabolites in Acute Schizophrenia
Post, R. M. (1975) · Archives of General Psychiatry · doi:10.1001/archpsyc.1975.01760260127011 · Cited by 203
Geller, E., Ritvo, E. R., Freeman, B. J., & Yuwiler, A. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207153070307 · Cited by 179
Anthony Altar, C., Wasley, A. M., Neale, R. F., & Stone, G. A. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90181-4 · Cited by 176
Serotonin-dopamine interactions in the nigrostriatal system
Waldmeier, P. C., & Delini-Stula, A. A. (1979) · European Journal of Pharmacology · doi:10.1016/0014-2999(79)90110-9 · Cited by 171
Ennis, C., Kemp, J. D., & Cox, B. (1981) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1981.tb00594.x · Cited by 163
The Antagonism of Amphetamine-Induced Symptomatology by a Neuroleptic
Angrist, B., LEE, H. K., & Gershon, S. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.7.817 · Cited by 150
Psychiatria, neurologia, neurochirurgia
van Praag, H. M. (1973) · Medical Entomology and Zoology · Cited by 147
Hormonal probes of central serotonergic activity: Do they really exist?
van Praag, H. M., Lemus, C. Z., & Kahn, R. S. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90134-x · Cited by 147
Self-citationPearlson, G. D., Garbacz, D. J., Breakey, W. R., Ahn, H. S., & DePaulo, J. R. (1984) · Psychiatry Research · doi:10.1016/0165-1781(84)90133-1 · Cited by 145
The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia
Meltzer, H. Y., Sommers, A., & Luchins, D. J. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198612000-00002 · Cited by 143
Langer, S. Z., Zarifian, E., Briley, M., Raisman‐Vozari, R., & Sechter, D. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90236-8 · Cited by 142
Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders
Stahl, S. M., Woo, D., Mefford, I. N., Berger, P. A., & Ciaranello, R. D. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.1.26 · Cited by 141
Biologic Heterogeneity and Psychiatric Research: Platelet MAO Activity as a Case Study
Buchsbaum, M. S., & Rieder, R. O. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780110017001 · Cited by 139
Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone
Ceulemans, D. L. S., Gelders, Y. G., Hoppenbrouwers, M. J. A., Reyntjens, A. M., & Janssen, P. A. J. (1985) · Psychopharmacology · doi:10.1007/bf00428197 · Cited by 134
Tritiated LSD Binding in Frontal Cortex in Schizophrenia
Whitaker, P. M. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780280046004 · Cited by 124
Serotonin and 5-Hydroxyindoleacetic Acid in Brains of Suicide Victims
Korpi, E. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800060088011 · Cited by 123
Increased Whole Blood Serotonin Concentrations in Chronic Schizophrenic Patients
DeLisi, L. E., Neckers, L. M., Weinberger, D. R., & Wyatt, R. J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780310047004 · Cited by 123
Clinical response of aggressive schizophrenics to oral tryptophan.
Morand, C., Young, S. N., & Fr, E. (1983) · PubMed · Cited by 105
Positive and Negative Schizophrenia Symptoms and the Role of Dopamine
Crow, T. J. (1981) · The British Journal of Psychiatry · doi:10.1192/bjp.139.3.251 · Cited by 100
Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles
Potkin, S. G., Weinberger, D. R., Linnoila, M., & Wyatt, R. J. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.1.21 · Cited by 100
Nybäck, H., Berggren, B.-M., Hindmarsh, T., Sedvall, G., & Wiesel, F. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90003-3 · Cited by 98
Acid Metabolites from Monoamines in Cerebrospinal Fluid of Chronic Schizophrenics
Persson, T., & Roos, B. (1969) · The British Journal of Psychiatry · doi:10.1192/bjp.115.518.95 · Cited by 97
Yuwiler, A., Brammer, G. L., Morley, J. E., Raleigh, M. J., Flannery, J. W., & Geller, E. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780310019001 · Cited by 96
Computed tomography (CT) findings in schizophrenia: Speculation on the meaning of it all
Weinberger, D. R. (1984) · Journal of Psychiatric Research · doi:10.1016/0022-3956(84)90035-9 · Cited by 94
Aberrant Monoamine Metabolite Levels in CSF and Family History of Schizophrenia
Sedvall, G. C. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780230031004 · Cited by 94
Biological suicide research: Outcome and limitations
van Praag, H. M. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90314-8 · Cited by 93
Altered platelet serotonin uptake kinetics in schizophrenia and depression
Kaplan, R. D., & Mann, J. J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90488-x · Cited by 82
Joseph, M. H., Baker, H. F., Crow, T. J., Riley, G. J., & Risby, D. (1979) · Psychopharmacology · doi:10.1007/bf00431959 · Cited by 80
Blood Tryptophan Metabolism in Chronic Schizophrenics
Freedman, D. X., Belendiuk, K., Belendiuk, G. W., & Crayton, J. W. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780310055005 · Cited by 77
Cowen, P. J., GADHVI, H., Gosden, B., & Kolakowska, T. (1985) · Psychopharmacology · doi:10.1007/bf00431703 · Cited by 74
Garelis, E., Gillin, J. C., Wyatt, R. J., & Neff, N. H. (1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.2.184 · Cited by 70
Goldstein, A. C., Himwich, H. E., Ss, K., & Smythies, J. (1967) · The American Journal of Psychology · doi:10.2307/1421213 · Cited by 69
Reynolds, G. P., Rossor, M. N., & Ll, I. (1983) · PubMed · Cited by 66
CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide
Roy, A., Ninan, P. T., Mazonson, A., Pickar, D., van Kammen, D., Linnoila, M., & Paul, S. M. (1985) · Psychological Medicine · doi:10.1017/s0033291700023618 · Cited by 64
Monoamines and monoamine metabolites in brains from demented schizophrenics
Winblad, B. G., Bucht, G., Gottfries, C. G., & Roos, B. E. (1979) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1979.tb00261.x · Cited by 63
Therapeutic indications for serotonin-potentiating compounds: A hypothesis
van Praag, H. M., Kahn, R. S., Asnis, G. M., Lemus, C. Z., & Brown, S. L. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90232-0 · Cited by 61
Self-citationUse of serotonergic agents in the clinical assessment of central serotonin function.
Dl, M., Mueller, E. A., Garrick, N. A., & Cs, A. (1986) · PubMed · Cited by 60
The action of neuroleptic drugs
Haase, H. J., & Janssen, P. A. J. (1985) · Elsevier eBooks · Cited by 57
CSF monoamine metabolites in schizophrenic patients
Gattaz, W. F., Waldmeier, P. C., & Beckmann, H. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb06717.x · Cited by 55
Platelet serotonin levels in schizophrenia: relationship to race and psychopathology.
Jackman, H. L., Luchins, D. J., & Meltzer, H. Y. (1983) · PubMed · Cited by 54
Differential response to amphetamine in schizophrenia
Cesarec, Z., & Nyman, A. K. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb05066.x · Cited by 53
Corbett, L., Christian, S. T., Morin, R. D., Benington, F., & Smythies, J. (1978) · The British Journal of Psychiatry · doi:10.1192/bjp.132.2.139 · Cited by 49
The negative symptoms of schizophrenia and the monoamine oxidase inhibitors
Bucci, L. (1987) · Psychopharmacology · doi:10.1007/bf00690936 · Cited by 49
Bowers, M. B. (1970) · Neuropharmacology · doi:10.1016/0028-3908(70)90011-0 · Cited by 45
Feldstein, A., Hoagland, H., & Freeman, H. (1959) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-195907000-00007 · Cited by 45
Double-Blind Controlled Study of L-Dopa Therapy in Schizophrenia
Inanaga, K., Nakazawa, Y., Inoue, K., Tachibana, H., Oshima, M., Kotorii, T., Tanaka, M., & Ogawa, N. (1975) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1975.tb02330.x · Cited by 41
Blood dimethyltryptamine concentrations in psychotic disorders.
Lipinski, J. F., MANDEL, L. R., Hs, A., Heuvel, W. J. A. V., & Rw, W. (1974) · PubMed · Cited by 39
Farley, I. J., Shannak, K. S., & Hornykiewicz, O. (1980) · PubMed · Cited by 39
Blood Platelet 5-Hydroxytryptamine Levels in Psychiatric Patients
Todrick, A., Tait, A. C., & Marshall, E. F. (1960) · Journal of Mental Science · doi:10.1192/bjp.106.444.884 · Cited by 36
King, R., Faull, K. F., Stahl, S. M., Mefford, I. N., Thiemann, S., Barchas, J. D., & Berger, P. A. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90018-6 · Cited by 34
Hetey, L. (1986) · Neuropharmacology · doi:10.1016/0028-3908(86)90157-7 · Cited by 34
Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients
Hy, M., Mb, D., Jackman, H. L., Rc, A., Tricou, B. J., & Young, M. H. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.10.1242 · Cited by 32
A test of the transmethylation hypothesis in acute schizophrenic patients
Carpenter, W. T., Fink, E. B., Narasimhachari, N., & Himwich, H. E. (1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.10.1067 · Cited by 30
Clinical effects of tryptophan in chronic schizophrenic patients.
Gillin, J. C., Kaplan, J. A., & Wyatt, R. J. (1976) · PubMed · Cited by 30
Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients.
Bigelow, L. B., Walls, P., Gillin, J. C., et al. (1979) · PubMed · Cited by 25
Platelet [3H]imipramine binding in autism and schizophrenia
Weizman, A., Gonen, N., Tyano, S., Szekely, G. A., & Rehavi, M. (1987) · Psychopharmacology · doi:10.1007/bf00690935 · Cited by 24
The Two-Syndrome Concept and Neuroendocrinology of Schizophrenia
Crow, T. J., Ferner, I. N., & Johnstone, E. C. (1986) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30637-3 · Cited by 23
Cerebrospinal Fluid Studies of Monoamine Metabolism in Schizophrenia
van Kammen, D. P., Peters, J. L., & van Kammen, W. B. (1986) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30636-1 · Cited by 22
Platelet serotonin concentration in schizophrenic patients
Kolakowska, T., & Molyneux, S. G. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.2.232 · Cited by 18
Cited by
Kalivas, P. W., & Stewart, J. (1991) · Brain Research Reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,019
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Meltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470
Metadata
- Authors
- Bleich, A., Brown, S.-L., Kahn, R., & van Praag, H. M.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1988-01-01
- Volume
- 14
- Issue
- 2
- Pages
- 297-315
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2118527319
- Cited by
- 371
- References
- 94
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.